Kimberly-Clark Sticks to 2026 Outlook, Beats Sales Estimates
Culture Index
Score Breakdown
Relevance
9/25
Freshness
25/25
Authority
25/20
Brand Signal
6/15
Depth
3/15
5-Axis Cultural Radar
Kimberly-Clark kept its annual forecast intact and beat first-quarter sales estimates on Tuesday, as the company expects to close its $40 billion acquisition of Tylenol and Neutrogena in the second half of 2026.
